Drug Free Solution Statistics
Total Valuation
DSOL has a market cap or net worth of 622,235.
| Market Cap | 622,235 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
DSOL has 444.45 million shares outstanding.
| Current Share Class | 444.45M |
| Shares Outstanding | 444.45M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2.81% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 296.16 |
| PB Ratio | -1.83 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.02
| Current Ratio | 0.02 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -1,270.07% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 255.79% |
| Weighted Average Cost of Capital (WACC) | 4.29% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +600.00% in the last 52 weeks. The beta is 0.01, so DSOL's price volatility has been lower than the market average.
| Beta (5Y) | 0.01 |
| 52-Week Price Change | +600.00% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.11 |
| Relative Strength Index (RSI) | 40.92 |
| Average Volume (20 Days) | 15,302 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, DSOL had revenue of 2,101 and -867,712 in losses. Loss per share was -0.01.
| Revenue | 2,101 |
| Gross Profit | -210,550 |
| Operating Income | -867,712 |
| Pretax Income | -867,712 |
| Net Income | -867,712 |
| EBITDA | -862,834 |
| EBIT | -867,712 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 7,124 in cash and n/a in debt, with a net cash position of 7,124 or 0.00 per share.
| Cash & Cash Equivalents | 7,124 |
| Total Debt | n/a |
| Net Cash | 7,124 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | -339,231 |
| Book Value Per Share | -0.00 |
| Working Capital | -384,362 |
Cash Flow
In the last 12 months, operating cash flow was -735,452 and capital expenditures -27,660, giving a free cash flow of -763,112.
| Operating Cash Flow | -735,452 |
| Capital Expenditures | -27,660 |
| Free Cash Flow | -763,112 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | n/a |
| Operating Margin | -41,299.95% |
| Pretax Margin | -41,299.95% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DSOL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -47.03% |
| Shareholder Yield | -47.03% |
| Earnings Yield | -139.45% |
| FCF Yield | -122.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2014. It was a forward split with a ratio of 3.
| Last Split Date | Jan 9, 2014 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
DSOL has an Altman Z-Score of -69.99 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -69.99 |
| Piotroski F-Score | 1 |